Welcome to our dedicated page for Augmedix news (Ticker: AUGX), a resource for investors and traders seeking the latest updates and insights on Augmedix stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Augmedix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Augmedix's position in the market.
Augmedix, Inc. (OTCQX: AUGX) reported Q1 2021 results, achieving $4.8 million in total revenue, a 21% increase from Q1 2020. Gross margin improved significantly to 44%, up 960 basis points year-over-year, while operating expenses rose to $6.5 million. The company recorded a net loss of $4.9 million, slightly higher than the prior year. Despite challenges from the pandemic, Augmedix expanded partnerships and reported a 113% net revenue retention rate from Health Enterprise customers. The firm maintains a cash position of $19.3 million.
Augmedix (OTCQX: AUGX), a leader in virtual medical documentation, will participate in the MGMA's 2021 Medical Practice Excellence: Pathways Conference Digital Experience from May 11-13. During their session titled “Intelligence and Human Pairing: The Best of Both Worlds in Healthcare,” attendees will explore the benefits of a hybrid human/AI approach in medical documentation. The conference emphasizes enhanced workflow and patient satisfaction through technology adoption in the healthcare sector, accelerated by the pandemic.
Augmedix, Inc. (OTCQX: AUGX) will release its first quarter 2021 financial results on May 13, 2021, after market close. A conference call is scheduled for 1:30 PM PT / 4:30 PM ET, accessible by dialing +1 (877) 407-3982 for U.S. participants or +1 (201) 493-6780 for international attendees.
Augmedix specializes in converting clinician-patient conversations into medical documentation, improving productivity and clinician satisfaction. Over a dozen U.S. health systems trust Augmedix, which supports multiple medical specialties and estimates a productivity increase of up to 20% for clinicians.
Augmedix (OTCQX: AUGX), a provider of remote medical documentation and clinical support, will participate in the 20th Annual Needham Virtual Healthcare Conference. Management is set to present on April 15, 2021, at 1:30 p.m. Eastern Time. A live and archived webcast will be available on the company’s website. Augmedix specializes in converting clinician-patient interactions into accurate medical documentation, allowing clinicians to save 2-3 hours daily and improve productivity by up to 20%. Visit augmedix.com for more information.
Augmedix has launched an enhanced version of its Notebuilder tool, a key component that uses natural language processing to create accurate medical documentation from real-time clinician-patient conversations. The update includes full documentation capabilities with sections for History of Present Illness, Physical Exam, and Assessment & Plan. The tool allows clinicians to customize notes and access medication databases efficiently while maintaining high accuracy and timeliness. This advancement aims to improve clinician workflow and increase productivity, potentially saving 2–3 hours daily per clinician.
Augmedix, Inc. (OTCQX: AUGX) reported Q4 2020 revenue of $4.5 million, a 15% increase from $4.0 million in Q4 2019. For the full year, revenue reached $16.5 million, up 17% from $14.1 million the previous year. Gross margin expanded to 44.2% in Q4, while operating expenses rose slightly to $5.6 million. The company faced a net loss of $3.8 million in Q4 and $12.5 million for 2020, with adjusted EBITDA losses decreasing by 15%. With $23 million in cash, Augmedix aims to leverage its $6 billion market opportunity to enhance physician productivity.
On March 30, 2021, Augmedix announced the refinancing of its long-term debt through a $15 million secured term loan with Eastward Capital Partners, with an additional $2 million available in 4Q21 contingent on financial goals. The loan allows Augmedix to pay down $13 million of existing debt and allocate remaining funds for working capital. CFO Paul Ginocchio emphasized improved financial flexibility and growth potential. Eastward Capital Partners expressed confidence in Augmedix's market opportunities and management capabilities.
Augmedix (OTC Pink: AUGX) reports preliminary financial results for Q4 and FY 2020, highlighting a 15% increase in Q4 revenue to $4.6 million and an approximate 17% annual growth to $16.5 million. Q4 gross margin improved to 44%, up from 34% a year prior, while annual gross margin reached 41%.
The company notes a decline in dollar-based net revenue retention to 108% in Q4 from 113% in Q3, and overall 114% for the year, down from 135% in 2019. As of December 31, 2020, cash holdings totaled $23 million.